Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Virus-like Particle based malaria vaccines targeting vulnerable epitopes in the circumsporozoite protein

Award Number: R01AI169739
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 11/09/2022
PERIOD OF PERFORMANCE END DATE: 10/31/2027

Group Awards By:

View Award Description

Virus-like Particle based malaria vaccines targeting vulnerable epitopes in the circumsporozoite protein - PROJECT SUMMARY The Plasmodium falciparum circumsporozoite protein (CSP) is an attractive malaria vaccine candidate because anti-CSP antibodies can block liver invasion and potentially provide sterilizing immunity against the parasite. However, current vaccines that target CSP, including RTS,S, the most advanced malaria vaccine, elicit suboptimal protective immunity that wanes dramatically over time. In this proposal, our goal is to engineer new and more effective vaccines targeting CSP. We will take advantage of the recent identification of potently protective monoclonal antibodies that target epitopes within novel sites of vulnerability in CSP. We will specifically target these epitopes using a highly immunogenic bacteriophage virus-like particle (VLP) vaccine platform technology. In preliminary data, we have shown that VLP-based immunogens targeting short epitopes within CSP can elicit high-titer and long-lasting antibody responses that inhibit Plasmodium infection of the liver and can prevent blood-stage infection in mice. In this proposal, we will utilize an arsenal of approaches to maximize the immunogenicity of VLP-based vaccines (Aim 1), we will use sensitive techniques to carefully monitor the B cell responses to our vaccines (Aim 2), and we will measure the effectiveness of vaccines in a state-of-the-art mouse infection model (Aim 3). Our team, which has expertise in vaccine engineering and design, B cell immunology, and malaria challenge models, will carry out these Aims with the ultimate goal of identifying a pre-erythrocytic malaria vaccine candidate suitable of advancing to clinical trials.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $611,029 )
2026	2026	UNIVERSITY OF NEW MEXICO	1 UNIVERSITY OF NEW MEXICO	ALBUQUERQUE	NM	87131	BERNALILLO	USA	Allergy and Infectious Diseases Research	000	4	12/4/2025	NON-COMPETING CONTINUATION	$611,029
														Subtotal = $611,029

Issue Date FY: 2025 ( Subtotal = $592,698 )
2025	2025	UNIVERSITY OF NEW MEXICO	1 UNIVERSITY OF NEW MEXICO	ALBUQUERQUE	NM	87131	BERNALILLO	USA	Allergy and Infectious Diseases Research	000	3	11/1/2024	NON-COMPETING CONTINUATION	$592,698
														Subtotal = $592,698

Issue Date FY: 2024 ( Subtotal = $611,029 )
2024	2024	UNIVERSITY OF NEW MEXICO	1 UNIVERSITY OF NEW MEXICO	ALBUQUERQUE	NM	87131	BERNALILLO	USA	Allergy and Infectious Diseases Research	000	2	10/27/2023	NON-COMPETING CONTINUATION	$549,926
2024	2024	UNIVERSITY OF NEW MEXICO	1 UNIVERSITY OF NEW MEXICO	ALBUQUERQUE	NM	87131	BERNALILLO	USA	Allergy and Infectious Diseases Research	001	2	5/13/2024	NON-COMPETING CONTINUATION	$61,103
														Subtotal = $611,029

Issue Date FY: 2023 ( Subtotal = $637,784 )
2023	2023	UNIVERSITY OF NEW MEXICO	2500 MARBLE DR NE	ALBUQUERQUE	NM	87131	BERNALILLO	USA	Allergy and Infectious Diseases Research	000	1	11/9/2022	NEW	$637,784
														Subtotal = $637,784

Grand Total All Awards = $2,452,540

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Virus-like Particle based malaria vaccines targeting vulnerable epitopes in the circumsporozoite protein

Award Number: R01AI169739

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 11/09/2022

PERIOD OF PERFORMANCE END DATE: 10/31/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer